In a report released yesterday, Jason Zemansky from Bank of America Securities reiterated a Buy rating on Travere Therapeutics (TVTX – ...

Travere Therapeutics offers rare kidney disease treatments with FDA-approved Filspari. Check out why I deem TVTX stock as a ...

Shortly after winning full FDA approval for its rare kidney disease drug Filspari, San Diego’s Travere Therapeutics has run ...

The US Food and Drug Administration (FDA) has converted the accelerated approval for Travere Therapeutics’ Filspari ...

Travere Therapeutics Inc (TVTX) reports a 77% increase in net product sales, driven by FILSPARI's performance, while ...

Shares in Travere Therapeutics have lost more than 40% of their value after the company said that a trial designed to confirm the benefits of its recently approved Filspari drug for rare kidney ...

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on ...

The final analysis showed treatment with sparsentan reduced the rate of decline in kidney function vs irbesartan. The Food and Drug Administration (FDA) has granted full approval to Filspari ...

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to Travere ...

Shares of Travere Therapeutics moved higher after the biopharmaceutical company said it won full Food and Drug Administration approval of its kidney-disease drug Filspari. Travere shares were ...

With full approval from the U.S. FDA in hand for Travere Therapeutics Inc.’s Filspari (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) who are at risk of ...